We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter
Read MoreHide Full Article
Stereotaxis (STXS - Free Report) recently announced the regulatory submissions for the MAGiC catheter, which is seeking marketing clearance in Europe and the United States.These submissions follow successful initial clinical results in an ongoing trial.
The company looks forward to working collaboratively with the regulatory agencies during their review of the submissions and hopes to make MAGiC catheter benefits available to patients and physicians soon.
Price Performance
In the past six months, STXS shares have gained 53.8% compared with the industry’s rise of 14.9%. The S&P 500 increased 14.9% in the same time frame.
Image Source: Zacks Investment Research
More on MAGiC Catheter
The Stereotaxis MAGiC catheter is a robotically guided magnetic ablation device intended for use in minimally invasive cardiac ablation treatments. Based on nearly two decades' worth of experience with over 100,000 procedures using robotically navigated ablation catheters, MAGiC includes several features intended to improve patient safety, procedural effectiveness and efficiency, and the doctor-patient experience.
The MAGiC catheter was used for the first time on humans earlier in 2024 as part of a clinical investigation that involved many centers. A renowned journal for electrophysiology received stellar preliminary data from the first 20 surgeries, indicating 100% acute effectiveness and no side effects. The regulatory submissions contained these results.
The MAGiC catheter's CE Mark and PMA Supplement filings are the result of a comprehensive process that involves design, development, manufacture, and testing. The catheter is the first of many interventional devices that Stereotaxis is developing, and it provides a framework for future advancements.
After obtaining regulatory permissions, Stereotaxis plans to commercially release the MAGiC catheter for robotic electrophysiologists’ use.
Industry Prospects
Per a report by Global Market Insights, the global electrophysiology market was estimated at $5.6 billion in 2022 and is expected to grow more than $17.1 billion by 2032 at a growth rate of 12%.
The rising prevalence of cardiac arrhythmia and heart failure among the population is likely to boost the market growth opportunities.
With the market potential for electrophysiology, Stereotaxis is likely to boost its business with its MAGiC catheter as it finds application in robotic electrophysiology.
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Cencora, Inc. (COR - Free Report) , Elevance Health, Inc. (ELV - Free Report) and Cardinal Health, Inc. (CAH - Free Report) .
Cencora, currently carrying a Zacks Rank of 2, reported first-quarter fiscal 2024 adjusted earnings per share (EPS) of $3.28, beating the Zacks Consensus Estimate by 14.7%. Revenues of $72.25 billion outpaced the consensus mark by 5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cencora has a long-term estimated growth rate of 8.6%. COR’s earnings surpassed estimates in the trailing four quarters, the average surprise being 6.7%.
Elevance Health reported fourth-quarter 2023 adjusted EPS of $5.62, beating the Zacks Consensus Estimate by 1.3%. Revenues of $42.45 billion outpaced the consensus mark by 1.5%. It presently carries a Zacks Rank #2.
Elevance Health has a long-term estimated growth rate of 12%. ELV’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.1%.
Cardinal Health reported second-quarter fiscal 2024 adjusted EPS of $1.82, beating the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion surpassed the Zacks Consensus Estimate by 1.1%. It currently carries a Zacks Rank #2.
Cardinal Health has a long-term estimated growth rate of 15.9%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 15.6%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter
Stereotaxis (STXS - Free Report) recently announced the regulatory submissions for the MAGiC catheter, which is seeking marketing clearance in Europe and the United States.These submissions follow successful initial clinical results in an ongoing trial.
The company looks forward to working collaboratively with the regulatory agencies during their review of the submissions and hopes to make MAGiC catheter benefits available to patients and physicians soon.
Price Performance
In the past six months, STXS shares have gained 53.8% compared with the industry’s rise of 14.9%. The S&P 500 increased 14.9% in the same time frame.
Image Source: Zacks Investment Research
More on MAGiC Catheter
The Stereotaxis MAGiC catheter is a robotically guided magnetic ablation device intended for use in minimally invasive cardiac ablation treatments. Based on nearly two decades' worth of experience with over 100,000 procedures using robotically navigated ablation catheters, MAGiC includes several features intended to improve patient safety, procedural effectiveness and efficiency, and the doctor-patient experience.
The MAGiC catheter was used for the first time on humans earlier in 2024 as part of a clinical investigation that involved many centers. A renowned journal for electrophysiology received stellar preliminary data from the first 20 surgeries, indicating 100% acute effectiveness and no side effects. The regulatory submissions contained these results.
The MAGiC catheter's CE Mark and PMA Supplement filings are the result of a comprehensive process that involves design, development, manufacture, and testing. The catheter is the first of many interventional devices that Stereotaxis is developing, and it provides a framework for future advancements.
After obtaining regulatory permissions, Stereotaxis plans to commercially release the MAGiC catheter for robotic electrophysiologists’ use.
Industry Prospects
Per a report by Global Market Insights, the global electrophysiology market was estimated at $5.6 billion in 2022 and is expected to grow more than $17.1 billion by 2032 at a growth rate of 12%.
The rising prevalence of cardiac arrhythmia and heart failure among the population is likely to boost the market growth opportunities.
With the market potential for electrophysiology, Stereotaxis is likely to boost its business with its MAGiC catheter as it finds application in robotic electrophysiology.
Stereotaxis Inc. Price
Stereotaxis Inc. price | Stereotaxis Inc. Quote
Zacks Rank & Other Stocks to Consider
STXS carries a Zacks Rank #2 (Buy) at present.
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Cencora, Inc. (COR - Free Report) , Elevance Health, Inc. (ELV - Free Report) and Cardinal Health, Inc. (CAH - Free Report) .
Cencora, currently carrying a Zacks Rank of 2, reported first-quarter fiscal 2024 adjusted earnings per share (EPS) of $3.28, beating the Zacks Consensus Estimate by 14.7%. Revenues of $72.25 billion outpaced the consensus mark by 5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cencora has a long-term estimated growth rate of 8.6%. COR’s earnings surpassed estimates in the trailing four quarters, the average surprise being 6.7%.
Elevance Health reported fourth-quarter 2023 adjusted EPS of $5.62, beating the Zacks Consensus Estimate by 1.3%. Revenues of $42.45 billion outpaced the consensus mark by 1.5%. It presently carries a Zacks Rank #2.
Elevance Health has a long-term estimated growth rate of 12%. ELV’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 3.1%.
Cardinal Health reported second-quarter fiscal 2024 adjusted EPS of $1.82, beating the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion surpassed the Zacks Consensus Estimate by 1.1%. It currently carries a Zacks Rank #2.
Cardinal Health has a long-term estimated growth rate of 15.9%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 15.6%.